Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company that regularly issues news and updates about its inflammation and immunology pipeline targeting the innate immune system. This news page aggregates company press releases and third-party coverage related to INmune Bio’s DN-TNF platform, CORDStrom™ mesenchymal stromal cell platform, and INKmune® natural killer cell priming platform.
Readers can find updates on XPro™ (XPro1595, pegipanermin), a selective soluble TNF neutralizer that the company is developing for neurological diseases driven by chronic inflammation. Recent news has highlighted Phase 2 MINDFuL trial results in early Alzheimer’s disease with inflammatory biomarkers, neuroimaging analyses using advanced MRI techniques, and manuscript submissions to peer-reviewed journals. The company also reports on scientific presentations at conferences such as the Clinical Trials on Alzheimer’s Disease (CTAD) meeting and the Alzheimer’s Association International Conference.
News related to the CORDStrom™ cell therapy platform includes clinical and manufacturing milestones in recessive dystrophic epidermolysis bullosa (RDEB), such as completion of a blinded randomized trial, pilot-scale commercial manufacturing runs at a cell and gene therapy manufacturing center in the United Kingdom, and intellectual property developments. INmune Bio also issues updates on participation in industry events and panels focused on dermatologic rare diseases and cell therapy manufacturing.
For the INKmune® platform, news items cover progress in the CaRe PC Phase I/II trial in metastatic castration-resistant prostate cancer, including reports that the trial met its primary and certain secondary endpoints, safety observations, and biomarker findings related to NK cell activation. Corporate news, including financing transactions, management changes, and special stockholder meetings, is also disclosed through regular press releases and corresponding SEC filings. Investors and researchers can use this page to follow INMB news on clinical data, regulatory plans, manufacturing scale-up, and corporate developments.
On May 23, 2022, INmune Bio (NASDAQ: INMB) announced that the FDA placed their Investigational New Drug (IND) application for XPro™ in Alzheimer's treatment on clinical hold, pending additional information regarding Chemistry Manufacturing and Controls (CMC). The official hold letter is expected in approximately 30 days. Meanwhile, the Phase 2 trial for XPro™ continues to enroll patients in Australia. XPro™ is designed to inhibit soluble TNF, potentially reducing neuroinflammation in neurologic diseases.
INmune Bio (NASDAQ: INMB) announced that David Moss, CFO, will present at the H.C. Wainwright Global Hybrid Investment Conference from May 23-26, 2022, at the Fontainebleau Hotel in Miami Beach, FL. The presentation is scheduled for May 24, 2022, at 10:00 AM ET. Moss will also be available for one-on-one meetings, which can be requested through the conference registration link. INmune Bio is focused on immunological therapies targeting the innate immune system, with several candidates in clinical trials for various conditions.
INmune Bio announced that data on XPro™'s ability to promote remyelination in a cuprizone model of multiple sclerosis will be presented on May 10, 2022. Research by Professor Lesley Probert reveals that XPro™ enhances macrophage phagocytosis of myelin debris, aiding in the remyelination process. Previous findings have indicated that XPro™ promotes remyelination in Alzheimer’s patients after a successful Phase I trial. This represents a promising development in neurodegenerative disease treatment.
INmune Bio (NASDAQ: INMB) has dosed its first patient in a Phase II trial for XPro1595, targeting mild Alzheimer’s disease. Financial results for Q1 2022 reveal a net loss of $6.9 million, up from $4.6 million the previous year, with revenues of $0.2 million. R&D expenses rose to $4.3 million, while cash reserves stood at $66.7 million as of March 31, 2022. Upcoming milestones include top-line results from pivotal trials expected in 2023, supporting the potential of their DN-TNF and INKmune platforms against various malignancies.
INmune Bio, Inc. (NASDAQ: INMB) is set to host a conference call and webcast on May 5, 2022, at 4:30 PM ET to discuss first-quarter results ending March 31, 2022, and provide a corporate update. The call can be accessed via dial-in numbers and a live audio webcast link. The company develops therapies targeting the innate immune system, with key products in clinical trials for conditions such as cancer and Alzheimer's disease. Investors are advised that outcomes of ongoing clinical trials remain uncertain as they await FDA approvals.
Boca Raton, FL, April 25, 2022 – INmune Bio (NASDAQ: INMB) announced participation in the B. Riley Neuro & Ophthalmology Conference on April 28, 2022. RJ Tesi, MD, President and CEO, will engage in a fireside chat at 11:00 am ET. This invitation-only event caters to B. Riley Securities' institutional clients. INmune Bio is focused on using the innate immune system to develop treatments for diseases such as cancer and Alzheimer's, with products like INB03™ and XPro™ in clinical trials.
INmune Bio (NASDAQ: INMB) has initiated patient enrollment for a crucial six-month Phase 2 trial assessing XPro1595 in patients with mild Alzheimer's disease (AD). This multicenter, randomized, placebo-controlled study aims to evaluate cognitive function and improvement in biomarkers associated with neuroinflammation. Following positive results from the Phase 1 trial, which showed a reduction in neuroinflammation and improvements in neurorepair biomarkers, the company anticipates enrolling 201 patients across the U.S., Australia, and Canada.
INmune Bio (NASDAQ: INMB) has announced significant findings regarding its product INB03 for treating trastuzumab-resistant MUC4 HER2+ breast cancer. Data from animal models indicate that INB03 effectively decreases MUC4 expression, reversing resistance to trastuzumab and tyrosine kinase inhibitors while enhancing an active tumor microenvironment. This research was presented at the American Association of Cancer Research Annual Meeting. Previous studies reveal MUC4 expression correlates with poorer survival outcomes. INB03 is poised for further clinical testing.
INmune Bio (NASDAQ: INMB) presented significant findings regarding its NK cell therapy, INKmune™, during the NK Cells in Solid Tumors workshop at the Innate Killer Summit. Dr. Mark Lowdell, the CSO, emphasized INKmune™'s unique ability to enhance NK cell survival and function in hostile tumor environments by upregulating mitochondrial proteins and nutrient receptors. Clinical data suggests that INKmune-primed NK cells can persist in the body for over 15 weeks, raising the potential for synergistic use with adoptive NK therapies. The company continues to explore collaborations for future clinical trials.
INmune Bio, Inc. (NASDAQ: INMB) announces that its Chief Scientific Officer, Dr. Lowdell, will lead a workshop at the 7th Innate Killer Summit in San Diego from March 30 to April 1, focusing on natural killer (NK) cells in treating solid tumors. The workshop aims to address challenges faced in NK cell therapies. Additionally, INmune will present case studies on INKmune™ showing promising results in three patients, including no side effects and improved disease outcomes. The company continues to advance its clinical trials targeting the innate immune system.